【摘要】 目的:评价国产塞曲司特颗粒剂治疗支气管哮喘的疗效和安全性。方法:非急性发作期哮喘病人213例随机分为塞曲司特组(A组)107例,均口服塞曲司特80mg·d-1,疗程8wk;孟鲁司特组(B组)106例,均口服孟鲁司特10mg·d-1,疗程8wk。观察病人临床疗效、肺通气功能疗效和不良反应。结果:临床有效率A组73.8％(79/107),B组75.5％(80/106)。肺通气功能有效率A组55.1％(59/ 107),B组55.7％(59/106)。其中轻度和中度哮喘病人的临床疗效和肺功能改善均较重度哮喘病人更佳(p<0.05)。不良反应发生率A组5.6％(6/107),B组4.7％(5/106),未见严重不良反应。上述指标2组间比较差异均无显著意义(P>0.05)。结论:塞曲司特与孟鲁司特治疗支气管哮喘的疗效相似,是治疗支气管哮喘的安全、有效的新药。更多还原

【Abstract】 AIM: To evaluate the efficacy and safety of domestic seratrodast granules in the treatment of asthma. METHODS: A total of 213 patients with asthma were randomly divided into two groups: seratrodast group (group A) and montelukast group (group B). One hundred and seven patients in group A were treated with seratrodast 80 mg, po, qd for 8 wk, and 106 patients in group B were treated with montelukast 10 mg, po, qd for 8 wk. The outcoming effects of clinical efficacy, lung function efficacy, and adverse reactions were compared between the two groups. RESULTS: The clinical efficacy rates and lung function efficacy rates were 73.8 % (79/107) vs 75.5 % (80/106) and 55.1 % (59/107) vs 55.7 % (59/106) in group A and group B, respectively. The clinical and lung function improvements showed much better in mild and moderate asthma patients than those with severe patients (P < 0.05) . The incidences of adverse reaction occurrence were 5.6 % (6/107) and 4.7 % (5/106) in group A and B, respectively, without serious cases in both groups and also no statistically significant difference between them (P>0.05). CONCLUSION: Seratrodast is a new, safe, and effective drug in treating patients with asthma and possesses reliable efficacy and less adverse reaction similar to montelukast.更多还原